A study observed that receiving two doses of COVID-19 vaccine significantly reduced the odds of unexplained sudden death.

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.